Clinical Trials Browser

OTHER × Uterine Cervical Neoplasms × tislelizumab × Clear all

NCT04802876 2025-03-21

ACROPOLI

Phase 2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05588219 2023-11-24

Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

Phase 2 Unknown

Uterine Cervical Neoplasms

NCT06039891 2023-09-15

Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer

Phase 2 Not yet recruiting

Uterine Cervical Neoplasms

NCT05511623 2023-09-11

Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

Phase 2 Recruiting

Uterine Cervical Neoplasms

NCT05614453 2023-06-29

ITTACC

Phase 2 Withdrawn

Uterine Cervical Neoplasms

NCT05247619 2022-07-15

A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

Phase 2 Unknown

Uterine Cervical Neoplasms

NCT05310383 2022-04-11

Tislelizumab and Radiotherapy for Recurrent Cervical Cancer

Phase 2 Unknown

Uterine Cervical Neoplasms